Randomized study comparing full dose monotherapy (S-1 followed by irinotecan) and reduced dose combination therapy (S-1/oxaliplatin followed by S-1/irinotecan) as initial therapy for older patients with metastatic colorectal cancer: NORDIC 9

S Winther; P Österlund; Å Berglund

Randomized study comparing full dose monotherapy (S-1 followed by irinotecan) and reduced dose combination therapy (S-1/oxaliplatin followed by S-1/irinotecan) as initial therapy for older patients with metastatic colorectal cancer: NORDIC 9

S Winther
, P Österlund
, Å Berglund

Research output: Contribution to journal › Article › Scientific › peer-review

14 Citations (Scopus)

Original language	English
Pages (from-to)	548
Journal	BMC Cancer
Volume	17
Issue number	1
Publication status	Published - 2017
Publication type	A1 Journal article-refereed

Publication forum classification

Publication forum level 1

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

https://pubmed.ncbi.nlm.nih.gov/28814275

Cite this

@article{c3e0f5e72bdb49b8aa1e64e6cacb724a,

title = "Randomized study comparing full dose monotherapy (S-1 followed by irinotecan) and reduced dose combination therapy (S-1/oxaliplatin followed by S-1/irinotecan) as initial therapy for older patients with metastatic colorectal cancer: NORDIC 9",

author = "S Winther and P {\"O}sterlund and {\AA} Berglund",

year = "2017",

language = "English",

volume = "17",

pages = "548",

journal = "BMC Cancer",

issn = "1471-2407",

publisher = "Springer Verlag",

number = "1",

}

Winther, S, Österlund, P & Berglund, Å 2017, 'Randomized study comparing full dose monotherapy (S-1 followed by irinotecan) and reduced dose combination therapy (S-1/oxaliplatin followed by S-1/irinotecan) as initial therapy for older patients with metastatic colorectal cancer: NORDIC 9', BMC Cancer, vol. 17, no. 1, pp. 548. <https://pubmed.ncbi.nlm.nih.gov/28814275>

Randomized study comparing full dose monotherapy (S-1 followed by irinotecan) and reduced dose combination therapy (S-1/oxaliplatin followed by S-1/irinotecan) as initial therapy for older patients with metastatic colorectal cancer: NORDIC 9. / Winther, S; Österlund, P; Berglund, Å.
In: BMC Cancer, Vol. 17, No. 1, 2017, p. 548.

Research output: Contribution to journal › Article › Scientific › peer-review

TY - JOUR

T1 - Randomized study comparing full dose monotherapy (S-1 followed by irinotecan) and reduced dose combination therapy (S-1/oxaliplatin followed by S-1/irinotecan) as initial therapy for older patients with metastatic colorectal cancer: NORDIC 9

AU - Winther, S

AU - Österlund, P

AU - Berglund, Å

PY - 2017

Y1 - 2017

M3 - Article

SN - 1471-2407

VL - 17

SP - 548

JO - BMC Cancer

JF - BMC Cancer

IS - 1

ER -